NASDAQ:CMPS
Compass Pathways PLC Stock News
$7.99
-0.290 (-3.50%)
At Close: May 16, 2024
2 Growth Stocks With Incredible Potential in the Next 5 Years
08:30am, Monday, 06'th Mar 2023
Biotech stocks are risky, but high-potential plays can pay off big. Compass Pathways is making progress towards commercializing its first therapy.
LONDON, March 02, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, ann
COMPASS Pathways plc to announce fourth quarter and year-end 2022 financial results on 28 February 2023
12:01pm, Friday, 24'th Feb 2023
Conference call to be held at 8:00am ET (1:00pm UK) Conference call to be held at 8:00am ET (1:00pm UK)
3 Cathie Wood Stocks That Could More Than Double in 12 Months, According to Wall Street
05:52am, Tuesday, 07'th Feb 2023
These stocks are risky. But they just might deliver huge gains if analysts are right.
7 Tempting Sin Stocks to Buy for Promising Profits
08:28pm, Monday, 06'th Feb 2023
Following a rough year, investors seeking positive returns might want to consider going a bit controversial with sin stocks. Understandably, with the political winds turning progressive, people nowada
The 7 Most Promising Psychedelic Stocks to Buy in February
02:30pm, Sunday, 05'th Feb 2023
Psychedelic stocks have seen remarkable progress in recent years, evolving from a fad to mainstream medicine. Several pharmaceutical companies are now investigating their potential therapeutic value.
Psychedelic Sunday: Competitive Strategies
11:45am, Sunday, 15'th Jan 2023
Stephen Tobin on investing in psychedelic stocks while they're still pre-revenue. Will first-movers get the advantage?
All You Need to Know About COMPASS Pathways PLC Sponsored ADR (CMPS) Rating Upgrade to Strong Buy
01:33pm, Friday, 13'th Jan 2023
COMPASS Pathways PLC Sponsored ADR (CMPS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Are Medical Stocks Lagging COMPASS Pathways (CMPS) This Year?
11:17am, Wednesday, 11'th Jan 2023
Here is how COMPASS Pathways PLC Sponsored ADR (CMPS) and Geron (GERN) have performed compared to their sector so far this year.
Scrutinizing Psychedelic Stocks
11:30am, Sunday, 08'th Jan 2023
What makes a psychedelic company compelling? Analyst Alex Carchidi has a background in biotech and focuses on long-term growth and risk management.
3 Biotech Stocks Aiming to Reinvent Mental Health Treatment
09:49pm, Tuesday, 06'th Dec 2022
Atai, Biogen, and Sage are working to develop new treatments for mental illness.
3 Big Trends Shaking Up Psychedelic Stocks
10:00am, Tuesday, 29'th Nov 2022
Major positive shifts are happening, but the field faces new headwinds too.
Compass Pathways uses psychoactive treatment for depression — CEO explains
08:19am, Saturday, 19'th Nov 2022
Biotech company Compass Pathways is up more than 100 since its IPO debut. The company aims to treat depression through psychedelic mushrooms and is backed by Peter Thiel.
COMPASS Pathways plc (CMPS) Q3 2022 Earnings Call Transcript
08:04am, Sunday, 06'th Nov 2022
COMPASS Pathways plc (NASDAQ:CMPS ) Q3 2022 Earnings Conference Call November 3, 2022 8:00 AM ET Company Participants Steven Schultz - SVP, IR George Goldsmith - Co-Founder and Executive Chairman Kabi
COMPASS Pathways plc to announce third quarter 2022 financial results on 3 November 2022
04:00pm, Wednesday, 26'th Oct 2022
LONDON, Oct. 26, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, anno
